Trial reportEye (London, England)2011
Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial.
Trial report in Eye (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03782051 (Combined Phacoemulsification and Viscocanalostomy With Ologen Implant Versus Combined Phacoemulsification and Viscocanalostomy), which is not on this map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combined Phacoemulsification and Viscocanalostomy With Ologen Implant Versus Combined Phacoemulsification and Viscocanalostomy
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Device-modified trabeculectomy for glaucoma.The Cochrane database of systematic reviews · 2023Pooled it
- Device-modified trabeculectomy for glaucoma.The Cochrane database of systematic reviews · 2015Pooled it
- Ologen implant versus mitomycin C for trabeculectomy: a systematic review and meta-analysis.PloS one · 2014Pooled it
- Efficacy of Ologen matrix implant in Ahmed Glaucoma Valve Implantation.Scientific reports · 2019Trial
- Combined phacoemulsification and viscocanalostomy with Ologen implant versus combined phacoemulsification and viscocanalostomy.BMC ophthalmology · 2019Trial
- Application of biodegradable collagen matrix (Ologen™) implants in Dacryocystorhinostomy surgeries, a randomized clinical study.BMC ophthalmology · 2018Trial
- Collagen matrix vs mitomycin-C in trabeculectomy and combined phacoemulsification and trabeculectomy: a randomized controlled trial.BMC ophthalmology · 2016Trial
- Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: five-year follow-up.BMC ophthalmology · 2016Trial
- Safety and efficacy of modified suture techniques in Ologen augmented trabeculectomy for eyes with advanced primary open angle and angle closure glaucoma.Indian journal of ophthalmology · 2026Article
- Phacoemulsification and Viscocanalostomy With or Without Silicone Implant in Primary Open-angle Glaucoma: A Randomized Clinical Trial.Journal of ophthalmic & vision research · 2026Article
- The Role of Biodegradable Collagen Matrices in Glaucoma Filtration Surgery: Practical Considerations in the Post-Ologen Era.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Clinical Impact of the Use of Ologen in Filtering Surgery Performed in Uncontrolled Glaucoma.Journal of clinical medicine · 2024Article
- [Wound healing after trabeculectomy : What and when in postoperative aftercare?]Die Ophthalmologie · 2024Article
- Comparison of surgical outcomes with and without Ologen collagen matrix augmentation during XEN gel stent implantation.BMC ophthalmology · 2022Article
- Comparison of bleb morphology by anterior segment optical coherence tomography and clinical outcome after phacotrabeculectomy with mitomycin C or Ologen implant.Indian journal of ophthalmology · 2021Article
- Preliminary results of Preserflo Microshunt versus Preserflo Microshunt and Ologen implantation.Eye and vision (London, England) · 2021Article
- A Narrative Review of the Complex Relationship between Pregnancy and Eye Changes.Diagnostics (Basel, Switzerland) · 2021Review
- Trabeculectomy with Ologen implant versus mitomycin C in congenital glaucoma secondary to Sturge Weber Syndrome.International journal of ophthalmology · 2018Article
- Ologen Implantation versus Conjunctival Autograft Transplantation for Treatment of Pterygium.Journal of ophthalmology · 2018Article
- [Management of Radius-Maumenee syndrome : Treatment with deep sclerectomy, viscocanalostomy and collagen matrix implantation].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo verify the safety and efficacy of Ologen (OLO) implant as adjuvant compared with low-dosage mitomycin-C (MMC) in trabeculectomy.
methodsThis was a prospective randomized clinical trial with a 24-month follow-up. Forty glaucoma patients (40 eyes) were assigned to trabeculectomy with MMC or OLO. Primary outcome includes target IOP at ≤21, ≤17, and ≤15 mm Hg; complete (target IOP without medications), and qualified success (target IOP regardless of medications). Secondary outcomes include bleb evaluation, according to Moorfields Bleb Grading System (MBGS); spectral domain optical coherence tomography (SD-OCT) examination; number of glaucoma medications; and frequency of postoperative adjunctive procedures and complications.
resultsThe mean preoperative IOP was 26.5 (±5.2) in MMC and 27.3 (±6.0) in OLO eyes, without statistical significance. One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009). The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively. The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP. The bleb height in OLO group was higher than MMC one (P<0.05). SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP ≤17 mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups. No adverse reaction to OLO was noted.
conclusionsOur results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.